Therefore, Notch1 activation may be a viable strategy for in vivo and ex vivo immunomodulation in applications such as DC-based tumor vaccines or vaccines against infectious agents or toxins (Weijzen et al., 2002), which verified that Eg.ferritin is a potential vaccine against cystic hydatid infection, which is consistent with our previous report (Wang et al., 2015). This evidence concerns the gene NOTCH1 and neoplasm.